Alimera Sciences Says Iluvien Effective at 3 Years
Iluvien, a sustained release drug-delivery system for the treatment of diabetic macular edema, may be getting closer to possible FDA approval. The parent company, Alimera Sciences has resubmitted additional safety and efficacy data as requested by the FDA last year. The FDA requested that they be given data extending for a 3 year period instead of the 2 years in the new drug application.